article thumbnail

Improving Sales: The Excuse Departement is Closed

Both Sides of the Table

Specifically what is often not in the DNA of founders are sales skills. The result is a lack of knowledge of the process and of sales people themselves. I had never had any sales training so everything we did for the first couple of years was instinctual. I boil it down to this: sales people are sales people.

Sales 316
article thumbnail

Selecting a Software Development Company in 2024

TechEmpower

Our blog post 53 Questions Developers Should Ask Innovators has a list of questions any good development team would ask. Inquisitiveness: Prior to starting the project, you should receive an estimate of the work effort. To provide an accurate estimate, the firm should ask a multitude of questions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Trump Team Outlines Healthcare Agenda—No Mention of Drug Prices

Xconomy

There is no mention of drug pricing or what the administration might do about frequent price increases, such as Mylan’s EpiPen practice, that critics say are unsubstantiated and unethical. It doesn’t necessarily allude to drug-price negotiation. In fact, the 2003 law signed by President George W.

Pricing 106
article thumbnail

Acadia, Neurocrine See Stock Price Bump After Quarterly Earnings

Xconomy

We’re in the midst of earnings season, and a couple of San Diego’s publicly traded biotechs recently updated investors this week with sales data and other financial insights. Here’s a look at those companies.

Pricing 61
article thumbnail

Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

Xconomy

It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

Pricing 73
article thumbnail

Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More

Xconomy

An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12 percent a year between now and 2024, when they will account for an estimated 20 percent of worldwide prescription drug sales. The market for drugs for rare or “orphan” diseases continues to grow.

Pricing 97
article thumbnail

Some Thoughts about Selling at Startups

Both Sides of the Table

Jeff (also an HBS alum) co-teaches the LTV course with Professor Eisenmann about a student of theirs who had written a blog post about sales taking on some of my previous assertions. That student is Erin McCann who formerly worked in sales at Google, so she has some ground to stand on in her assertions.

Startup 319